Core Insights - An international team led by scientists from the University of Liverpool has developed a new antibiotic named Novltex, which shows sustained inhibitory effects against various deadly superbugs, marking significant progress in the fight against antibiotic resistance [1][2] - Antibiotic resistance is listed as one of the top ten health threats to humanity, causing nearly 5 million deaths annually, with the WHO highlighting the urgent need for new antibiotics [1] - Novltex targets lipid II, a crucial component of bacterial cell walls that is less prone to mutation, offering durable resistance protection against antibiotic resistance [1][2] Summary by Sections Development and Testing - Novltex was inspired by the existing antibiotics Teixobactin and Clofazimine, avoiding the use of expensive raw materials and allowing for the construction of numerous candidate molecules for optimization [2] - The antibiotic demonstrates sustained antibacterial capabilities, remaining effective at low doses and outperforming existing antibiotics like Vancomycin and Daptomycin, with no toxicity to human cells [2] Significance and Potential - The combination of efficiency, durability, and scalability makes Novltex one of the most promising antibiotic candidates in decades [2] - The synthetic efficiency of Novltex is reported to be 30 times higher than that of natural products, enhancing its potential for mass production [2]